Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$20.94 - $38.01 $709,866 - $1.29 Million
33,900 New
33,900 $1.21 Million
Q4 2022

Feb 14, 2023

BUY
$25.44 - $59.78 $841,326 - $1.98 Million
33,071 Added 32.69%
134,248 $3.65 Million
Q3 2022

Nov 14, 2022

BUY
$43.66 - $61.0 $715,194 - $999,241
16,381 Added 19.32%
101,177 $5.45 Million
Q2 2022

Aug 15, 2022

BUY
$28.82 - $77.35 $1.72 Million - $4.62 Million
59,793 Added 239.14%
84,796 $3.42 Million
Q1 2022

May 16, 2022

SELL
$48.25 - $100.49 $917,570 - $1.91 Million
-19,017 Reduced 43.2%
25,003 $1.66 Million
Q4 2021

Feb 14, 2022

BUY
$88.71 - $120.43 $3.24 Million - $4.4 Million
36,516 Added 486.62%
44,020 $4.4 Million
Q2 2021

Aug 16, 2021

SELL
$109.77 - $165.68 $1.66 Million - $2.51 Million
-15,150 Reduced 66.88%
7,504 $932,000
Q1 2021

May 17, 2021

BUY
$127.04 - $179.1 $2.32 Million - $3.28 Million
18,299 Added 420.18%
22,654 $3.46 Million
Q4 2020

Feb 16, 2021

BUY
$99.96 - $135.93 $108,056 - $146,940
1,081 Added 33.02%
4,355 $561,000
Q3 2020

Nov 16, 2020

BUY
$80.32 - $111.8 $262,967 - $366,033
3,274 New
3,274 $366,000
Q4 2019

Feb 14, 2020

SELL
$59.49 - $82.78 $394,835 - $549,410
-6,637 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$62.59 - $110.3 $755,023 - $1.33 Million
-12,063 Reduced 64.51%
6,637 $424,000
Q2 2019

Aug 14, 2019

BUY
$63.94 - $91.11 $1.2 Million - $1.7 Million
18,700 New
18,700 $1.61 Million
Q1 2019

May 15, 2019

SELL
$34.3 - $97.98 $3.28 Million - $9.38 Million
-95,700 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$29.2 - $46.1 $2.79 Million - $4.41 Million
95,700 New
95,700 $3.6 Million

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $4.82B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.